Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Hyatt Hotels Corporation (H) Price & Performance

Hyatt Hotels CorporationTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Hyatt Hotels Corporation — how do they compare? GSK plc trades at $50.41 (market cap $102.60B), while Hyatt Hotels Corporation trades at $177.1 (market cap $16.27B). The key difference: GSK plc is far larger — about 6.3× Hyatt Hotels Corporation's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

GSKH
Market Cap
$102.60B$16.27B
Sector
HealthConsumer Cyclical
52-Week High
$61.18$202.09
52-Week Low
$38.22$135.42
Enterprise Value
$123.04B$20.17B
Dividend Yield
3.57%0.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Hyatt Hotels Corporation

Hyatt Hotels Corp (H) trades at $176.29, up 3.65% today, with a bearish technical outlook but strong recent earnings beats. The stock shows a high P/E of 213.14 and modest net margin of 1.1%, while cash flow trends are volatile. Analyst consensus is mixed with a $199.55 price target, and recent news highlights valuation concerns amid growth initiatives.

Outlook balances operational momentum from fee growth and RevPAR gains against rich valuation and debt risks. Investment opportunity lies in sustained travel demand, but risks include project delays, regional weakness, and high leverage. The stock requires patience for growth to justify premium multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Hyatt Hotels Corporation

Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.

Read more on H